San Antonio-The Prostate Cancer Prevention Trial (PCPT) showed conclusively that finasteride (Proscar), a 5-alpha-reductase inhibitor indicated for the treatment of BPH, reduced the incidence of prostate cancer by nearly 25%. Continuing analysis of data from that trial now show the drug also enhances detection of prostate cancer by significantly improving the specificity of the PSA assay, according to a study published recently in the Journal of the National Cancer Institute (2006: 98:1128-33).
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.